If you have been treated for HCV before, here are the recommendations for re-treatment for all genotypes from the American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA):

AASLD HCV Re-treatment Recommendations for Patients Who Failed Prior Peginterferon and Ribavirin Treatment without Decompensated Cirrhosis or Certain Co-existing Medical Conditions, such as HIV or Kidney Disease
Recommended Alternative
Genotype 1a
(no cirrhosis)
Daklinza + Sovaldi for 12 weeks
OR
Harvoni for 12 weeks
OR
Olysio + Sovaldi for 12 weeks
OR
Viekira Pak + ribavirin for 12 weeks
Prior responder-relapsers: Olysio + PEG** + ribavirin for 12 weeks, followed by 12 ,ore weeks of Peg + ribavirin (24 weeks total treatment) with/without cirrhosis***
Prior partial, null or non-responders: Olysio + PEG** + ribavirin for 12 weeks, followed by 36 more weeks of PEG + ribavirin (48 weeks total treatment) with/without cirrhosis***
Genotype 1a
(with compensated cirrhosis)
Daklinza + Sovaldi with/without ribavirin for 24 weeks
OR
Harvoni for 24 weeks
OR
Harvoni + ribavirin for 12 weeks
OR
Olysio + Sovaldi with/without ribavirin for 24 weeks without Q80K polymorphism
OR
Viekira Pak + ribavirin for 24 weeks
n/a
Genotype 1b
(no cirrhosis)
Daklinza + Sovaldi for 12 weeks
OR
Harvoni for 12 weeks
OR
Olysio + Sovaldi for 12 weeks
OR
Viekira Pak for 12 weeks
n/a
Genotype 1b
(with compensated cirrhosis)
Daklinza + Sovaldi with/without ribavirin for 24 weeks
OR
Harvoni for 24 weeks
OR
Harvoni + ribavirin for 12 weeks
OR
Olysio + Sovaldi with/without
ribavirin for 24 weeks
OR
Viekira Pak for 12 weeks
n/a
Genotype 2 Sovaldi + ribavirin for 12 to 16 weeks Sovaldi + ribavirin + PEG** for 12 weeks
Genotype 3
(no cirrhosis)
Daklinza + Sovaldi for 12 weeks
OR
Sovaldi + ribavirin + PEG** for 12 weeks
Sovaldi + ribavirin for 24 weeks
Genotype 3
(with compensated cirrhosis)
Daklinza + Sovaldi + ribavirin for 24 weeks (unable to take PEG)
OR
Sovaldi + ribavirin + PEG** for 12 weeks
n/a
Genotype 4 Harvoni for 12 weeks
OR
Sovaldi + ribavirin + PEG** for 12 weeks
OR
Sovaldi + ribavirin for 24 weeks
OR
Technivie + ribavirin for 12 weeks
n/a
Genotype 5 Harvoni for 12 weeks Sovaldi + ribavirin + PEG** for 12 weeks
Genotype 6 Harvoni for 12 weeks Sovaldi + ribavirin + PEG** for 12 weeks



AASLD HCV Re-treatment Recommendations for Patients Who Failed Prior Treatment  with Sovaldi (sofosbuvir) + Ribavirin, with/without PEG**
Recommended Alternative
Genotype 1
(no cirrhosis)
Harvoni + ribavirin for 12 weeks n/a
Genotype 1
(with cirrhosis)
Harvoni + ribavirin for 24 weeks n/a
Genotype 2 Daklinza + Sovaldi with/without ribavirin for 24 weeks (unable to take PEG)
OR
Sovaldi + ribavirin + PEG** for 12 weeks
n/a
Genotype 3 Daklinza + Sovaldi + ribavirin for 24 weeks (unable to take PEG)
OR
Sovaldi + ribavirin + PEG** for 12 weeks
n/a



AASLD HCV Re-treatment Recommendations for Patients Who Failed Prior Treatment with Peginterferon, Ribavirin, and an HCV Protease Inhibitor (Incivek, Olysio, Victrelis) or Failed Olysio + Sovaldi
Recommended Alternative
Genotype 1
(no cirrhosis)
Daklinza + Sovaldi for 12 weeks
OR
Harvoni for 12 weeks
Harvoni + ribavirin for 12 weeks if failed prior treatment with Olysio + Sovaldi
Genotype 1
(with cirrhosis)
Daklinza + Sovaldi with/without ribavirin for 24 weeks
OR
Harvoni for 24 weeks
OR
Harvoni + ribavirin for 12 weeks (not recommended for cirrhotic patients who previously failed Olysio + Sovaldi)
Harvoni + ribavirin for 24 weeks if failed prior treatment with Olysio + Sovaldi



* When more than one treatment is recommended, they are listed alphabetically
** PEG = peginterferon
*** FDA-approved revisions to the prescribing information 09/2015

Last Revised: January 4, 2016